Chiu, T.L. and Su, C.C. (2009) Curcumin Inhibits Proliferation and Migration by Increasing the Bax to Bcl-2 Ratio and Decreasing NF-kappaBp65 Expression in Breast Cancer MDA-MB-231 Cells. International Journal of Molecular Medicine, 23, 469-475.
https://doi.org/10.3892/ijmm_00000153

has been cited by the following article:

• TITLE: The Inhibitory Effect of Curcumin on Ornithine Decarboxylase against Hepatic Carcinoma

  AUTHORS: Abeer A. Khamis, Amira H. Sharshar, Amal H. Mahmoud, Tarek M. Mohamed

  KEYWORDS: Curcumin-HepG2 Cells-Apoptosis, Ornithine Decarboxylase, Bax, Cell Cycle

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.7 No.5, May 20, 2019

  ABSTRACT: Curcumin the active component of turmeric is widely used as an anticancer agent for treating many human cancers. This study aimed at the extraction of curcumin from Curcuma Longa and investigates its therapeutic effect as ornithine decarboxylase (ODC) inhibitor in HepG2 cells. The proliferation of HepG2 cells was carried out by using the MTT assay. In addition, cell cycle analysis was evaluated by using the flow-cytometric technique. Our results showed that curcumin has the ability to inhibit the proliferation of HepG2 cells with IC50 of 24.79 μg/ml and induced G2/M cell cycle arrest. Moreover, it caused an elevation in the intracellular concentration of Ca2+. Moreover, in the curcumin administration the downregulation expression level of ODC and Bcl-2 genes (p ≤ 0.05) was significant found. On the other hand, upregulation in the expression level of P53, Bax, and caspase-3 genes (p ≤ 0.05). This study concluded that curcumin may be considered as a new saving candidate for the future progress of antitumor agents.